Immunotherapy in Melanoma | Specialty

UC Davis Meets NCI-Designation With Great Responsibility

November 30th 2015

Conference Highlights, Three FDA Approvals, and More

November 30th 2015

FDA Issues Complete Response Letter for Nivolumab in BRAF-Mutant Melanoma

November 27th 2015

The FDA has requested additional data for the use of single-agent nivolumab in previously untreated patients with BRAF V600 mutation-positive advanced melanoma.

Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma

November 27th 2015

Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.

Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in Melanoma

November 25th 2015

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

European Commission Approves Vemurafenib/Cobimetinib Combo for Melanoma

November 25th 2015

The European Commission has approved the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) as a treatment for patients with BRAF-positive metastatic or unresectable melanoma.

Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma

November 25th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib plus trametinib versus vemurafenib plus cobimetinib.

FDA Approves Frontline Nivolumab for Advanced Melanoma

November 24th 2015

The FDA has expanded the approval for single-agent nivolumab (Opdivo) to include the frontline treatment of patients with BRAF wild-type advanced melanoma.

FDA Approves First-Line Nivolumab for Advanced Melanoma

November 24th 2015

Vemurafenib/Cobimetinib Shows 30% OS Benefit in BRAF-Mutant Melanoma

November 22nd 2015

Treatment with the combination of vemurafenib and cobimetinib improved overall survival by 4.9 months compared with vemurafenib alone for patients with BRAF mutation-positive advanced melanoma.

Pembrolizumab/Ipilimumab Combo Effective in Advanced Melanoma

November 22nd 2015

A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.

Factors Affecting Dabrafenib/Trametinib Outcomes in Melanoma Identified

November 22nd 2015

In the largest-to-date analysis of treatment-naïve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.

Novel Pembrolizumab Combos Show Promising Responses in Melanoma

November 21st 2015

Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.

Understanding BRAF Resistance Critical to Advancing Melanoma Care

November 21st 2015

Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.

Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated Melanoma

November 21st 2015

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

November 21st 2015

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.

James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations

November 20th 2015

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

FDA Grants Dabrafenib/Trametinib Full Approval for BRAF-Mutant Melanoma

November 20th 2015

The FDA has granted a full approval to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAF-mutated melanoma.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

November 20th 2015

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.